•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AptarGroup, Inc. (NYSE: ATR)
Dividend Champion, Contender, And Challenger Highlights: Week of November 8
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting
Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)
Investing in AptarGroup (ATR)? Don't Miss Assessing Its International Revenue Trends
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
Aptar: 3 Key Takeaways for Long-Term Investors
Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November
Dividend Champion, Contender, And Challenger Highlights: Week November 1
AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript
What AptarGroup (ATR) Said on Its Q3 Earnings Call
AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates
Aptar Reports Third Quarter 2026 Results
Aptar Increases Quarterly Dividend to $0.50 Per Share
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program
AptarGroup, Inc. $ATR Stock Bought by State of Alaska Department of Revenue
AptarGroup, Inc. (ATR) – What Are Brokerages Saying About This Stock?
AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner